A Study of CX157 (TriRima) for the Treatment of Depression
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the efficacy of CX157 60 mg administered three times
a day (180 mg daily dose) as compared to placebo in subjects with Major Depressive Disorder
(MDD). Secondary objectives are to evaluate the safety and tolerability and steady state
pharmacokinetic profile of CX157 in these subjects.